

# Balaxi Pharmaceuticals Limited

To  
Listing Department,  
National Stock Exchange of India Limited.  
Exchange Plaza, Plot No C/1, G Block, Bandra Kurla Complex,  
Bandra (E), Mumbai-400051

19<sup>th</sup> July, 2021

Stock Code: **BALAXI**

**Sub: Intimation under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Newspaper clippings published on 19<sup>th</sup> July, 2021, in Business Standard (English) and Nava Telangana (Regional(Telugu) Edition) regarding the un-audited Standalone and Consolidated financial results of the Company for the 1<sup>st</sup> quarter ended 30<sup>th</sup> June, 2021.

The above information is also available on the website of the Company at [www.balaxipharma.in](http://www.balaxipharma.in)

This is for your information and record.

Yours Faithfully,  
For Balaxi Pharmaceuticals Limited,

  
Chinta Shalini  
Company Secretary



**Registered Office:**

2<sup>nd</sup> Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: [info@balaxi.in](mailto:info@balaxi.in) | Website: [www.balaxipharma.in](http://www.balaxipharma.in)

(Formerly known as Balaxi Ventures Limited)



# Clinical trials on five-year olds and above to start soon: Zydus

SOHINI DAS  
Mumbai, 18 July

Ahmedabad-based pharmaceutical major Cadila Healthcare (Zydus Cadila) is planning to start clinical trials soon on children aged five years and above for its deoxyribonucleic acid (DNA) plasmid technology-based Covid-19 vaccine, claimed a senior executive.

Meanwhile, the company is awaiting approval from the Drugs Controller General of India (DCGI) for its vaccine ZyCoV-D. It has sought approval for use in children above 12 years, and has already submitted safety and tolerability data from the Phase 2 clinical trials. It has generated the data on 1,000 adolescents (between 12 years and 18 years) from its Phase 3 trials as well. The 1,000-volunteer data will be submitted to the regulator soon.

"We plan to start trials on children aged five years and above if the regulator approves," said Sharvil Patel, managing director of Zydus Cadila. So far, no other vaccine has been approved globally for children below 12 years. India's Bharat Biotech is now in the middle of conducting clinical trials on children above two years for the Covaxin.

If things go well, ZyCoV-D could be the first approved vaccine for ad-



## INJECTING HOPE

- ▶ Zydus plans to start clinical trials of its vaccine on five years and above
- ▶ Three-dose regimen of vaccine on Day Zero, Day 28, Day 56
- ▶ Two-dose regimen trial data shows equivalent immune response
- ▶ Will be administered through PharmaJet — a needle-free system Tropis
- ▶ Stored at 2-8 degrees C, but stable at 25 degrees C for at least three months

lescents in India. Zydus has also claimed that its vaccine works against the Delta variant. Trials carried out in more than 50 clinical sites spread across the country and during the peak of the second wave of Covid-19 have shown the vaccine's efficacy against the new mutant strains, especially the Delta variant.

At the moment, the DCGI and its expert committee are reviewing the data submitted by Zydus from a 28,000-people Phase 3 efficacy trial. According to sources, the subject expert committee is likely to take up the review of ZyCoV-D this week. So far, the regulator and experts have been studying the data submitted.

ZyCoV-D has shown 66.6 per cent efficacy in interim analysis of Phase 3 trials, and can be stored at 25 degrees Celsius for three months. It is a three-dose vaccine given on Day Zero, Day 28, and Day 56.

No moderate case of Covid disease was observed in the vaccine arm after administration of the third dose — suggesting 100 per cent efficacy for moderate disease. No severe cases or deaths due to Covid occurred in the vaccine arm after administration of the second dose of the vaccine, the company claimed.

Meanwhile, Zydus has also submitted the immunogenicity data

from a two-dose regimen (using 3 milligram doses) trial to the DCGI, which shows 'equivalent immunogenicity' with that of the three-dose regimen. Patel is thus hopeful that there will be a 'good discussion point' with the regulator for approval for a two-dose regimen.

Conventional active vaccines are made from a killed or weakened form of the infectious agent. DNA plasmid vaccine is a relatively new approach, where a piece of DNA containing the genes for the antigens is injected. The body then learns to develop an immune response against the antigen, and when the actual pathogen attacks, the body is able to generate the specific antibodies against it.

DNA vaccines, Zydus has claimed, have been shown to stimulate sustained immune responses.

ZyCoV-D efficacy is in the range of Johnson & Johnson's single-dose vaccine, which uses a human adenovirus vector Ad26 — a 66.3 per cent efficacy in preventing Covid illness.

As for the Oxford-AstraZeneca vaccine, the World Health Organization notes on its website, "The AZD1222 vaccine against Covid-19 has an efficacy of 63.09 per cent against symptomatic SARS-CoV-2 infection."

Bharat Biotech's Covaxin has shown 77.6 per cent efficacy against symptomatic Covid illness from interim analysis of Phase 3 trials, while Russia's Sputnik V has shown 97.8 per cent efficacy against severe Covid disease in an 81,000-subject trial in the UAE recently.



"It is indeed good news for travellers, as we see sixteen European countries recognising COVISHIELD as an acceptable vaccine for entry."  
@adarpoonawalla

▶ FROM PAGE 1

# 'India will always remain a key talent hub'



beneficiaries. We had our fintech partnerships and our tech pipes are full.

**Citi has always been a net hirer and exporter of top-drawer talent to other markets. Will the sale have an impact on that?**

India will always remain a key talent hub for Citi because of the quality of resources. The rotation of talent worldwide is not random; it's an organised thought process. None of that will change — we have 23,000 employees and will end the year with 25,000. We have been adding 3,000 on average every year. This includes client solutions centres. I see the pace continuing and India will carry on being a place to hire for Citi.

**Given the Covid-19 pandemic, how have your clients from middle market enterprises (MMEs) to Indian companies and multinationals adapted? Do you see India potentially emerging as a strong China+1 contender, given there is a new world order with supply chains and economies being created?**

There was always a great opportuni-

ty for India because of diversification. This is now even more attributable to Covid-19 and the whole China+1 strategy. No one is going to leave China because it's a large market.

But I would say that the Government of India itself has been watchful of these opportunities — the tax and land reforms, the infrastructure push, and production-linked incentives have been notable. The game, however, for supply chains is long term. From that view, India has a great hand to play.

We, of course, have a lot of multinational target clients whom we talk to try and see the India opportunity.

We are naturally positioned because of our global network. In our customer base, if we start with the MMEs, we see textile players doing offline garment designing move fast to sophisticated software; fast food companies making the switch to home deliveries, and still others setting up personal protective equipment lines as new ventures.

If you see the kind of transactions Reliance did and raised capital at the height of the pandemic, it never

missed a beat.

By and large, our client base has been very resilient; the smart people have been proactive in raising capital.

**Do you believe India will see more fundraising?**

Equity market activity, environmental, social and governance activity, special purpose acquisition company activity — the markets are on fire because the interest rates are attractive and the 10-year treasury bills are low to 1.3 per cent.

The money is cheap and available in plenty. The whole liquidity game is very much alive.

Everyone is expecting sharp recovery, despite the second wave. In India, for the first six months, there has already been \$15 billion of equity-raising and as much in debt.

We just saw strong response to the Zomato initial public offering. There are a number of consumer tech and health tech players who will contribute to the strong flow of companies going public.

I am confident about the capital markets and the mergers and acquisitions.

# Adani's airport business sees new appointments

ANEESH PHADNIS  
Mumbai, 18 July

The Adani group has put in place a new organisation structure as it looks to consolidate and grow its airport business.

RK Jain, chief executive officer of Mumbai airport has been elevated as the CEO of the group's airport division. Jain who has been associated with Mumbai International Airport Limited (MIAL) since its inception will also look after the Mumbai airport slum development project and regulatory issues, the group said in a staff announcement.

Jain takes over from Behnad Zandi who will oversee the non aeronautical business at the group level.

Prakash Tulsiani will replace Jain as the new CEO of Mumbai airport. Tulsiani who was earlier the CEO of All Cargo Logistics joined Adani group's airport division a few months ago and was in charge of operations.

The changes were announced on Saturday and comes close on the heels of group's acquisition of MIAL from the GVK group.

The Adanis had six airports in their portfolio and with the addition of Mumbai airport the group will control control 25 per cent of

passenger footfalls and 33 per cent of India's air cargo and make the group India's largest airport infrastructure company.

In other changes, Captain BVJK Sharma, will be in charge as the CEO of Navi Mumbai airport.

Sharma was earlier the director of ports in Adani Ports and Special Economic Zone Limited. The group has announced that construction work of the greenfield airport in Navi Mumbai will begin next month and financial closure for the project will be completed in ninety days. The group hopes to start the airport in 2024.

BG Gandhi, CEO of Krishnapatnam port will assume role of chief airport officer of Ahmedabad airport. Prabhat Mahapatra, head of operations of MIAL will now be in charge of operations at all group airports in his new role as head operations, Centre of Excellence. Manoj Katar, COO of Dahe port will replace Mahapatra.

Nirav Shah and Vishnu Jha have been appointed as chief airport officers of Mangaluru and Jaipur airports respectively. Rekha Nair, head of airport service at MIAL will take over as head of customer experience and quality for the group's airport division.



# BSNL cuts loss to ₹7,441 crore due to lower wages on VRS

PRESS TRUST OF INDIA  
New Delhi, 18 July

State-run telecom firm BSNL has narrowed its consolidated loss to ₹7,441.11 crore in the financial year ended on March 21, according to an official.

The company had posted a loss of ₹15,499.58 crore in 2019-20.

"The loss has come down mainly due to reduction in employee wages on account of voluntary retirement opted by 78,569 employees," an official of the company said.

The revenue from operations of the company declined by 1.6 per cent to ₹18,595.12 crore in 2020-21 compared to ₹18,906.56 crore it reported in 2019-20, the BSNL official said.

The state-owned telecom company's net worth has come down to ₹51,686.8 crore during FY2021 from ₹59,139.82 crore in the previous year.

The outstanding debt of the company increased to ₹27,033.6 crore in FY2020-21 from ₹21,674.74 crore in the financial year 2019-20.

**EICHER**  
**EICHER MOTORS LIMITED**

CIN : L34102DL1982PLC129877  
Registered Office: 3rd Floor-Select Citywalk, A-3 District Centre, Saket, New Delhi - 110017  
Corporate Office: #96, Sector 32, Gurugram - 122001, Haryana  
Telephone: +91 124 4415600  
Email: investors@eichermotors.com  
Website: www.eichermotors.com

**39TH ANNUAL GENERAL MEETING TO BE HELD THROUGH VIDEO CONFERENCING**

Notice is hereby given that 39th Annual General Meeting (AGM) of members of Eicher Motors Limited ("the Company") is scheduled to be held on Tuesday, August 17, 2021, at 1.00 P.M. IST through Video Conferencing (VC) in compliance with applicable provisions of the Companies Act, 2013 and SEBI (LODR) Regulation, 2015 and circulars issued thereunder, to transact the business items as set out in the notice of AGM which shall inter alia contain the instructions for joining AGM through VC.

Members holding shares in physical form and who have not registered their email ids/bank account details, are requested to visit [https://linkintime.co.in/emailreg/email\\_register.html](https://linkintime.co.in/emailreg/email_register.html) portal of Link Intime India Pvt. Ltd., Registrar & Share Transfer Agent of the Company and register their email ids/bank account details, in order to receive a copy of AGM Notice, Annual Report and login details for remote voting/e-voting through email and those holding shares in demat form are requested to contact their respective Depository Participant (DP), for the aforesaid purpose and follow the process advised by DP.

Members will have an opportunity to cast their vote remotely on the business items as set out in notice of AGM, through remote e-voting/e-voting at AGM. The manner of casting vote through remote e-voting/e-voting system including those by physical shareholders or by shareholders who have not registered their email ids, shall be provided in notice of AGM. Copy of the AGM notice along with Annual Report for financial year 2020-21 and login details for such voting, will be sent to all the members whose email addresses are registered with the Company/DP in due course.

The aforesaid notice of 39th AGM along with Annual Report will be made available on the website of the Company i.e. at [www.eichermotors.com](http://www.eichermotors.com) and on the website of stock exchanges viz. BSE and NSE at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) respectively. The above information is also available on the said websites.

Notice is also hereby given that pursuant to Section 91 of the Companies Act, 2013 and Regulation 42 of the SEBI (LODR) Regulation, 2015, the Register of Members and Share Transfer Books of the Company will remain closed from August 11, 2021 to August 17, 2021 (both days inclusive) for determining the eligibility of payment of Dividend of Rs. 17/- per equity share of face value of Re. 1/- each for the financial year ended March 31, 2021 as recommended by the Board, in its meeting held on May 27, 2021.

For Eicher Motors Limited  
Sd/-  
Manhar Kapoor  
General Counsel &  
Company Secretary

Date : July 18, 2021  
Place : Gurugram, Haryana

**सेंट्रल बैंक ऑफ इंडिया**  
**Central Bank of India**

NOTICE

"Central Bank of India intends to invite quotes for Canteen Services. Please see our website [www.centralbankofindia.co.in](http://www.centralbankofindia.co.in)"

Place: Mumbai  
Date: 16 Jul 2021  
Chief Security Officer

**Punjab & Sind Bank**  
(A Govt. of India Undertaking)

TENDER NOTICE

Sealed tenders are invited for "Selection of Vendor for procurement, installation and maintenance of New ADF-MIS (Automated Data Flow & Management Information System) including Hardware and Software and its integration with Core Banking, CIMS, SFMS, ADEPT (Automated Data Extraction Project) Solution and various other applications". For specifications and other relevant details, please visit Bank's website [www.punjabandsindbank.co.in](http://www.punjabandsindbank.co.in). Any further changes related to the said Tender shall be posted on Bank's website only.  
Dy. General Manager (IT)

**AkzoNobel**  
**Akzo Nobel India Limited**

CIN : L24292WB1954PLC021516  
Tel. No.: 033 2226 7462 Fax No.: 033 2227 7925  
Email: investor.india@akzonobel.com Website: www.akzonobel.co.in

NOTICE

NOTICE is hereby given that the 67<sup>th</sup> Annual General Meeting ("AGM") of the members of the Company will be held on Friday, 13 August, 2021 at 2:30 p.m. (IST) through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") facility to transact the business set out in the Notice of AGM dated 22 May, 2021 in compliance with all the applicable provisions of the Companies Act, 2013 and the Rules made thereunder and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with General Circular Nos. 14/2020, 17/2020 and 20/2020 dated 8<sup>th</sup> April, 2020, 13<sup>th</sup> April, 2020 and 5<sup>th</sup> May, 2020, respectively and by General Circular No. 02/2021 dated 13<sup>th</sup> January, 2021 issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India (SEBI) vide its circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated 12<sup>th</sup> May, 2020 read with circular no. SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated 15<sup>th</sup> January, 2021.

The Notice of the AGM and Annual Report has been sent through electronic mode to the members whose e-mail IDs are registered with the Company's Registrar & Transfer Agent/Depository Participants. The aforesaid documents are also available on Company's website at [www.akzonobel.co.in](http://www.akzonobel.co.in) as well as on the website of the Stock Exchanges, i.e., [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com), where the shares of the Company are listed. Members who need assistance for attending the AGM, may please call toll free no. 18001205764.

**Book Closure:** The Register of Members and the Share Transfer Books of the Company will remain closed from 07<sup>th</sup> day of August, 2021 to 13<sup>th</sup> day of August, 2021 (both days inclusive) for taking record of the Members of the Company for the purpose of AGM and payment of final dividend for the financial year ended 31 March, 2021, if approved at the 67<sup>th</sup> AGM.

**Dividend and Record Date:** As recommended by the Board of Directors of the Company and if approved at the AGM, final dividend @ Rs 30 per share shall be paid within 30 days from the date of AGM. Company has fixed 6<sup>th</sup> day of August, 2021 as the Record Date for determining entitlement of members to final dividend for the financial year ended 31 March 2021. A member, whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the close of business hours of 6<sup>th</sup> day of August, 2021, shall be entitled for dividend.

**E-voting:** The Company is providing its members, facility to exercise their right to vote at the 67<sup>th</sup> AGM by electronic means and the business as set out in the Notice may be transacted through remote e-Voting Services provided by National Securities Depository Limited (NSDL). The cut-off date for determining the eligible members, who can vote at AGM, will be 6<sup>th</sup> day of August, 2021. E-voting window will open at 9:00 a.m. on 10<sup>th</sup> day of August, 2021 and closes at 5:00 p.m. on 12<sup>th</sup> day of August, 2021. For electronic voting instructions, shareholders may go through the instructions in the Notice of 67<sup>th</sup> AGM and in case of any queries/grievances connected with the electronic voting, shareholders may refer the Frequently Asked Questions (FAQs) and e-voting user manual for the shareholders available at <https://www.evoting.nsdl.com> or call toll free no. 18001020990 and 1800224430.

for Akzo Nobel India Limited

Registered Office:  
Geetanjali Apartment, 8B Middleton Street, Kolkata – 700071

Harshi Rastogi  
Company Secretary  
Membership #A13642

Place: Gurugram  
Date: 19 July 2021

**Balaxi Pharmaceuticals Limited**

Registered Office: 2<sup>nd</sup> Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.  
CIN: L25191TG1942PLC121598  
Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in  
(Formerly known as Balaxi Ventures Limited)

**Extract Of Unaudited Standalone And Consolidated Financial Results For The Quarter Ended 30th June, 2021**

(₹ in Lakhs, unless specified)

Sl. No.	Particulars	STANDALONE			CONSOLIDATED		
		Quarter ended 30.06.2021 Unaudited	Quarter ended 31.03.2021 Audited	Quarter ended 30.06.2020 Unaudited	Quarter ended 30.06.2021 Unaudited	Quarter ended 31.03.2021 Audited	Quarter ended 30.06.2020 Unaudited
1.	Total Income from Operations						
2.	Net profit/(loss) for the period (before tax, exceptional and/or extraordinary items)	2918.04	2259.71	2115.27	5833.53	5295.31	5205.84
3.	Net profit/(loss) for the period before tax (after exceptional and/or extraordinary items)	593.41	460.55	629.02	1249.11	996.92	1046.49
4.	Net profit/(loss) for the period after tax (after exceptional and/or extraordinary items)	443.25	315.95	470.69	1071.37	836.10	870.30
5.	Total Comprehensive Income for the period [Comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	443.25	315.95	470.69	1071.37	836.10	870.30
6.	Equity share capital	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
7.	Reserves (excluding Revaluation Reserve) as per the Audited Balance Sheet of the previous year						
8.	"Earnings Per Share (of Rs.10/- each) (not annualised)						
	1. Basic (amount in Rs.)	4.43	3.16	4.71	10.71	8.36	8.70
	2. Diluted (amount in Rs.)	4.43	3.16	4.71	10.71	8.36	8.70

Notes:  
a. The above is an extract of the detailed format of quarter ended 30th June, 2021 Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Statement of Unaudited Standalone and Consolidated Financial Results is available on the website of the Stock Exchange at [www.nseindia.com](http://www.nseindia.com) (NSE) and on the Company's website at [www.balaxipharma.in](http://www.balaxipharma.in).  
b. The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 17th July, 2021 and have been subjected to Limited Review by the Statutory Auditors of the Company. The said Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.

For and on behalf of Board of Directors,  
**Balaxi Pharmaceuticals Limited**  
Ashish Maheshwari  
Managing Director

Place: Hyderabad  
Date: 17th July, 2021



